Heterogeneity of anti-β2-glycoprotein I antibodies

Marielle Sanmarco; Nathalie Bardin; Miri Blank; Veronique Pascal; Marie Christine Alessi; Françoise Dignat-George; Yehuda Shoenfeld; Jean Robert Harlé

doi:10.1160/TH04-04-0230

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2005; 93(01): 80-87
DOI: 10.1160/TH04-04-0230

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Heterogeneity of anti-β2-glycoprotein I antibodies

A factor of variability in test results

Autoren

Marielle Sanmarco

¹Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
Nathalie Bardin

¹Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
Miri Blank

²Department of Medicine 'B' and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
Veronique Pascal

¹Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
Marie Christine Alessi

³Laboratoire d’Hématologie, Hôpital de La Timone, Marseille, France
Françoise Dignat-George

⁴INSERM U 608, Laboratoire d’Hématologie et d’Immunologie, UFR de Pharmacie, Marseille, France
Yehuda Shoenfeld

²Department of Medicine 'B' and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
Jean Robert Harlé

⁵Service de Médecine Interne, Hôpital de La Conception, Marseille, France

Abstract

Summary

The aim of this study was to evaluate the heterogeneity of IgG-anti- β₂ -glycoprotein I antibodies (IgG-aβ₂ GPI) as regarding their reactivity pattern against different sources of human β₂ GPI,their avidity and their association with clinical events of antiphospholipid syndrome (APS).Three thousand six hundred and eightyfour consecutive patient sera were routinely tested for IgG-a β₂ GPI over 1 year using an in-house ELISA with 2 different commercial preparations of human purified β₂GPI. Of the 340 sera found positive, all those clinically documented were included in this study; 61 were positive with only one preparation (S1) and 59 with both (S2).The results of ELISA were confirmed by Western blot. Heterogeneity was stressed by testing sera with a human recombinant protein and 3 β₂ GPI-related peptides. No contribution of glycosylation in the binding to β₂GPI was found.The avidity indices for each protein were significantly higher in S1 than in S2 (p = 0.0021). S2 were more associated with antiphospholipid antibodies than S1 (75% versus 21% ; p <0.0001).A similar frequency of the main clinical features of APS was found in S1 and S2 sera (69% and 71%, respectively). In conclusion, our data show a heterogeneity in the antigenic reactivity pattern of IgG- a β₂ GPI and a relationship between a binding profile and antibody avidity.This heterogeneity could represent a crucial factor of variability in test results and underlines the difficulty of getting standardisation.

Keywords

β2-glycoprotein I - heterogeneity - avidity - antiphospholipid syndrome

Volltext

Referenzen

References
1 Najmey SS, Keil LB, Adib DY. et al The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci 1997; 27: 41-6.
2 Wilson WA, Gharavi AE, Koike T. et al International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
3 Asherson RA, Khamashta MA, Ordi-Ros J. et al The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore). 1989; 68: 366-74.
4 Alarcon-Segovia D, Deleze M, Oria CV. et al Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989; 68: 353-65.
5 Reber G, Schousboe I, Tincani A. et al Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
6 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-4.
7 Bouma B, de Groot PG, van den Elsen JM. et al Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
8 Schwarzenbacher R, Zeth K, Diederichs K. et al Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39.
9 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
10 Roubey RA, Eisenberg RA, Harper MF. et al "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
11 Tincani A, Spatola L, Prati E. et al The antibeta2- glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species’ evolution. J Immunol 1996; 157: 5732-8.
12 Matsuura E, Igarashi Y, Yasuda T. et al Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
13 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
14 McNeeley PA, Dlott JS, Furie RA. et al Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
15 Igarashi M, Matsuura E, Igarashi Y. et al Human beta2-glycoprotein I as an anticardio-lipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 3262-70.
16 Koike T, Ichikawa K, Atsumi T. et al Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction. J Autoimmun 2000; 15: 97-100.
17 Blank M, Shoenfeld Y, Cabilly S. et al Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 5164-8.
18 Verrot D, SanMarco M, Dravet C. et al Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33-7.
19 Vlachoyiannopoulos PG, Petrovas C, Tektonidou M. et al Antibodies to B2-GPI: Urea resistance, binding , specificity and association with thrombosis. J Clin Immunol 1998; 18: 380-91.
20 Cabral AR, Amigo MC, Cabiedes J. et al The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472-81.
21 Shoenfeld Y, Krause I, Kvapil F. et al Prevalence and clinical correlations of antibodies against six β 2-glycoprotein I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23: 375-81.
22 Schousboe I. Characterization of subfractions of beta 2-glycoprotein I: evidence for sialic acid microheterogeneity. Int J Biochem 1983; 15: 35-44.
23 Gries A, Nimpf J, Wurm H. et al Characterization of isoelectric subspecies of asialo-beta 2-glycoprotein I. Biochem J 1989; 260: 531-4.
24 Brighton TA, Dai YP, Hogg PJ. et al Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Biochem J 1999; 340: 59-67.
25 Arvieux J, Roussel B, Ponard D. et al IgG2 subclass restriction of anti-b2 glycoprotein 1 antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
26 Zanon E, Prandoni P, Vianello F. et al Antibeta2- glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999; 96: 269-74.
27 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-906.
28 Bruce IN, Clark-Soloninka CA, Spitzer KA. et al Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria : a single center study and literature review. J Rheumatol 2000; 27: 2833-7.
29 Day HM, Thiagarajan P, Ahn C. et al Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25: 667-74.
30 Forastiero RR, Martinuzzo ME, Carreras LO. Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot. Clin Exp Immunol 1999; 118: 480-6.
31 Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid- negative patients with thrombosis: a case control study. Thromb Haemost 2002; 88: 729-32.
32 Galli M, Luciani D, Bertolini G. et al Antibeta2- glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
33 Lynch A, Byers T, Emlen W. et al Association of antibodies to beta2-Glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension : a prospective study in low-risk pregnancy. Obstet Gynecol 1999; 93: 193-8.
34 Franklin RD, Hollier N, Kutteh WH. Beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000; 73: 531-5.
35 Gris JC, Quere I, Sanmarco M. et al Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study-NOHA. Thromb Haemost 2000; 84: 228-36.